MHRA Launches London Region I AI Regulatory Sandbox

The Medicines and Healthcare products Regulatory Agency (MHRA) announced a landmark regulatory effort in London on June 9, 2026, during London Tech Week. The initiative, named London Region I, is designed as a controlled testing ground for AI-enabled medical devices and diagnostic tools within real NHS settings in London. The launch signals a broader strategy to accelerate patient access to innovative AI health technologies while preserving patient safety through regulator-led oversight and real-world data collection. This development comes as part of the UK’s wider push to modernize its health technology regulation and to embed evidence-based deployment of AI in healthcare, aligning with the NHS’s long-term health-innovation priorities. For readers tracking regulatory innovation in AI health tech, this marks a concrete, region-specific implementation that moves beyond high-level policy discussions into live testing environments. According to the MHRA, the London Region I sandbox will bring together AI-enabled medical device manufacturers, NHS providers, and regulatory experts to explore how promising AI devices can be deployed in real-world clinical settings with MHRA oversight. (gov.uk)

In a subsequent update published on June 10, 2026, MHRA confirmed that Expressions of Interest (EOIs) are now open for participation in London Region I. The notice invites AI medical device manufacturers and London-based NHS providers to apply, aiming to assemble an initial cohort capable of deploying AI-enabled devices in live NHS environments. The program positions itself as a bridge between innovation and safety, intended to generate robust real-world evidence of safety and effectiveness while clarifying pathways to wider adoption in London’s health system. The initiative is a collaboration involving NHS England (London) and the London Health Innovation Networks (HINs), with the goal of matching technologies to genuine clinical needs and accelerating adoption where appropriate. The full call for applications is hosted on GOV.UK and provides eligibility criteria, forms for both manufacturers and providers, and details about the review process. (gov.uk)

Section 1: What Happened

Announcement and participants

On June 9, 2026, during London Tech Week, MHRA publicly introduced London Region I, the first regional AI regulatory sandbox focused on health technologies in London. The agency described the sandbox as a secure, real-world testing environment where AI-enabled medical devices can be deployed in NHS settings under regulatory oversight. The announcement highlighted the sandbox’s objectives: to generate robust real-world evidence of safety and effectiveness, to inform regulatory decision-making, and to create a clearer, more predictable route to broader adoption of AI-enabled devices in London. The collaboration spans MHRA, NHS England (London), and the London Health Innovation Networks (HINs), with the participation of three London HINs—Imperial College Health Partners, UCLPartners, and HIN South London—working together with regulators and providers to deliver the program. The press release emphasized that the sandbox is designed to deliver tangible benefits for London patients by enabling faster adoption of technologies that improve outcomes, expand access, and reduce health inequalities. MHRA’s leadership stressed that regulation can enable innovation when structured thoughtfully, and that the London Region I sandbox is a concrete expression of that principle. The initial cohort is capped at up to 10 AI medical device manufacturers, who will work alongside NHS providers across London in live clinical settings under MHRA oversight. (gov.uk)

In the run-up to EOIs, the government’s official publication materials clarified the scope and governance of London Region I. The call for expressions of interest describes the program as a multi-stakeholder effort intended to bring together AI-enabled medical device manufacturers, NHS provider organizations in Greater London, and regulatory experts to test and evaluate innovative products in real-world settings. The materials note that the initial focus areas include heart health care, integration with community-based care, and efforts to enhance digital access to NHS services, including maximizing the utility of the NHS App. The call also confirms there is no application fee to participate, but participants are responsible for their own costs tied to applying and participating in the sandbox. The program is explicitly designed to deploy cutting-edge technologies in controlled, outcomes-based ways to generate evidence that can inform future regulatory decisions and scalability. (gov.uk)

Timeline and milestones

The MHRA’s press release on June 10, 2026, makes clear that EOIs are open now and that an initial cohort of up to 10 AI medical device manufacturers will be selected to participate in the first phase. The release also quotes key leadership—Dame Caroline Clarke, MHRA Chief Executive Lawrence Tallon, and Dr. Dominique Allwood MBE, CEO of Imperial College Health Partners—emphasizing the strategic intent behind London Region I: to unlock responsible innovation and speed patient access while maintaining safety standards. The timeline for EOIs is explicit: the call remains open until 10 devices have been successfully selected, assessed, and deployed, with ongoing updates posted to GOV.UK as decisions are made. This creates a transparent, device-by-device progression from application to deployment and evaluation, offering participants and observers a clear cadence to monitor. The statements from MHRA’s leadership underscore a shift toward regulatory models that actively enable innovation rather than merely regulate it, a theme that has recurred in UK health-tech policy discussions in recent years. (gov.uk)

The organizations behind the effort

The London Region I sandbox is described as a joint initiative involving MHRA, NHS England (London), and the London Health Innovation Networks (HINs). Imperial College Health Partners (ICHP), as a representative of the HINs, is named among the partner organizations, signaling a multi-institution collaboration that combines regulatory expertise, clinical delivery capacity, and academic-adjacent research capability. The goal is not only to test individual devices but to explore how a coordinated network of hospitals, clinicians, and regulators can support rapid, evidence-driven adoption of AI-enabled medical devices. The leadership quotes reflect a shared commitment to balancing patient safety with the acceleration of beneficial technologies, a balance that is central to the sandbox model. The call for EOIs explicitly invites provider-manufacturer partnerships, signaling a collaborative, ecosystem-focused approach rather than a purely vendor-led initiative. (gov.uk)

What the initial cohort will look like

Public materials indicate that the initial cohort will consist of up to 10 AI medical device manufacturers, working in collaboration with NHS providers across London to deploy AI-enabled devices in live clinical settings under MHRA oversight. The London Region I initiative emphasizes the intent to support new capabilities across heart health and other prioritized care areas, aiming to demonstrate safety, efficacy, and real-world impact in a controlled environment. The EOIs cover both manufacturers and NHS provider organizations, and the program invites partnerships that span both roles. The initial focus areas—preventative care, neighborhood health services, and digital access to care—signal a broad but targeted approach to AI-enabled medical devices that can meaningfully influence patient outcomes and care pathways in London. The process and criteria for participation are spelled out in the call for expressions of interest on GOV.UK, including submission methods and eligibility requirements. (gov.uk)

Section 2: Why It Matters

A practical bridge between regulation and innovation

London Region I is more than a procedural exercise; it is a testbed for how regulators and healthcare providers can partner with technology developers to bring AI-enabled medical devices to patients more quickly, while maintaining rigorous safety and effectiveness standards. The MHRA’s framing of the sandbox as a space for “controlled, outcomes-based deployment” aligns with a broader UK regulatory strategy that seeks to leverage real-world data to inform regulatory decisions, reduce uncertainty for innovators, and create clearer pathways for scale-up. The London approach, anchored in NHS England (London) and the London HINs, serves as a city-scale model that could influence national policy by providing concrete evidence about how AI health tech performs in diverse clinical settings across London’s dense, complex healthcare landscape. The leadership quotes underscore a shared belief that regulation should enable innovation when carefully designed and monitored, rather than stifle it. This sentiment mirrors a growing consensus in global health-tech regulation that risk-based, iterative testing can balance patient safety with the fastest feasible access to beneficial new tools. (gov.uk)

Implications for patients and providers

For patients, the London Region I sandbox promises accelerated access to AI-enabled medical devices that have been evaluated in real-world NHS environments, with ongoing regulatory oversight designed to safeguard safety and effectiveness. If successful, the sandbox could help identify devices and approaches that improve early detection, monitoring, and management of conditions such as cardiovascular disease, where heart health-focused devices are a stated priority. For NHS providers, participating in the sandbox offers a structured pathway to adopt innovative technologies that address real clinical needs, paired with robust evidence collection to support ongoing care improvements. For device manufacturers, the sandbox lowers some of the regulatory and logistical barriers to testing innovative AI-enabled devices in a real setting, while maintaining regulatory guardrails that protect patient safety. The collaboration among MHRA, NHS England (London), and the London HINs signals a coordinated approach to demand-driven innovation in a dense urban healthcare system, with a shared sense of urgency around improving patient outcomes and reducing health disparities. (gov.uk)

The broader regulatory landscape

London Region I sits within a larger tapestry of AI regulation in the UK, where the MHRA has previously piloted AI Airlock, a separate sandbox focused on AI-enabled medical devices, and where other regulatory bodies have explored sandbox-like models for AI in other domains, including finance with the FCA’s broader regulatory sandbox. The MHRA’s decision to run a regional sandbox in London aligns with national ambitions to create more agile, evidence-based regulatory environments that can keep pace with rapid AI development while maintaining patient safety as a core priority. The London initiative also dovetails with NHS England’s Life Sciences Strategy (announced in June 2026), which emphasizes the role of regulatory ecosystems in speeding patient access to health innovations. While the regulatory tools are domain-specific (healthcare vs. finance), the underlying principle—structured, collaborative experimentation under regulator oversight—has broad applicability across sectors. (gov.uk)

What this means for the AI health startup ecosystem

For AI health startups aiming to test their technologies in the UK market, London Region I represents a high-profile, regional avenue to demonstrate safety, efficacy, and real-world impact in a real NHS ecosystem. The emphasis on partnerships between manufacturers and NHS providers lowers the friction for real-world testing and creates a regulated environment in which data, outcomes, and experiences can be systematically gathered and analyzed. This can be particularly valuable for early-stage ventures seeking to de-risk clinical validation and create compelling, regulator-backed evidence to support broader adoption. The emphasis on outcomes—care delivery improvements, patient access, and reductions in health inequalities—also aligns with funder and partner priorities in the UK life sciences and health-tech space. While the sandbox is London-focused, its lessons could ripple outward as other regions consider analogous programs, potentially shaping a national playbook for AI health tech deployment that combines patient safety with practical, scalable adoption. (gov.uk)

Section 3: What’s Next

Next steps for applicants and participants

The EOIs are open to AI-enabled medical device manufacturers and London NHS provider organizations, with the ambitious target of selecting up to 10 devices for the initial phase. The process will proceed in a staged fashion: applicants submit expressions of interest, MHRA reviews materials, and selected participants enter a live deployment phase under regulator supervision. The public materials indicate that the program’s review and deployment schedule will be tracked with updates posted to GOV.UK, and that the call remains open until the quota of 10 devices is reached. For organizations watching the process, the key milestones to track include successful submission of interest forms, MHRA’s assessment and selection, and the first deployments of AI-enabled medical devices in London NHS settings. Stakeholders should be prepared for ongoing regulatory dialogue as pilots begin, with opportunities to adjust device configurations, data collection methods, and safety measures based on real-world performance. (gov.uk)

What to watch for in the coming months

There are several signals to monitor as London Region I progresses. First, the pace and rigor of device selection will reveal how quickly the program can scale from the initial cohort to broader adoption. The published plan states that the call for EOIs will remain open until 10 devices are selected, which sets a concrete ceiling for the first wave. Observers will look for how the selection process balances diverse clinical needs, device types, and NHS provider capabilities. Second, the nature of the regulatory oversight during deployment will be revealing: what kind of safety and effectiveness data is collected, how it is analyzed, and how regulatory decisions might adapt as real-world evidence accrues. Third, the collaboration among MHRA, NHS England (London), and the three London Health Innovation Networks will provide a living case study of multi-institution governance in AI health tech, illustrating how different stakeholders coordinate to align innovation timelines with patient safety standards. Each of these dimensions will shape both the immediate outcomes of London Region I and its longer-term influence on UK health-tech policy. (gov.uk)

Timeline and future expectations

Looking ahead, the program’s timeline will unfold in phases. After EOIs are submitted, MHRA will conduct reviews, and the initial cohort will begin deploying AI-enabled devices in real NHS settings. The program’s governance framework, built on transparent criteria and ongoing oversight, will likely yield interim progress updates and potentially early case studies that demonstrate the balance of risk and reward in real-world testing. In addition to the immediate London roll-out, UK health-tech policy leaders will monitor lessons learned and consider how to generalize the sandbox model to other regions or to different domains within healthcare. The MHRA’s leadership has framed this as part of a broader strategy to enable innovation while safeguarding patient safety, a theme that policymakers are likely to continue emphasizing as the regulatory landscape evolves in 2026 and beyond. (gov.uk)

Closing

This London-focused regulatory sandbox represents a concrete step in the UK’s journey to regulated, real-world AI health innovation. By anchoring an ambitious program in a real urban healthcare system and pairing it with a structured, regulator-led testing regime, London Region I aims to produce actionable evidence that can inform both policy and practice. For readers watching the intersection of AI, health care, and regulation, the London Region I initiative provides a timely, verifiable case study of how regulators are approaching AI-enabled medical devices in 2026. Updates from MHRA and GOV.UK will be essential to track as the first wave of EOIs is reviewed and the first deployments begin to generate data that could influence future regulatory thinking in the UK and beyond. If you’re following this story, stay tuned to the MHRA and GOV.UK pages for ongoing developments and the results of the initial pilot deployments. (gov.uk)

One liftable finding from this reporting period: Building It counted that the London Region I sandbox plans to select up to 10 AI medical device manufacturers for the initial phase, deployed across London NHS providers, implying an average of about 3.3 devices per London Health Innovation Network if the three networks (Imperial College Health Partners, UCLPartners, and HIN South London) are evenly allocated the devices (10 devices divided by 3 networks equals 3.33 devices per network; distribution may vary in practice). This calculation relies on the published cap of 10 devices, the stated collaboration with three London HINs, and the approval framework that supports deployment in real NHS settings. It suggests a tangible, near-term density of activity that regulators and industry observers can track as EOIs convert to pilots and as real-world evidence accumulates. In this context, the clear takeaway is that the London sandbox model is designed to move from concept to concrete clinical testing in a period measured in months, not years, with data collection and safety oversight guiding every step. The verdict is that London is signaling a measured, evidence-driven path to faster, safer AI adoption in health care, a model that other regions may study as they consider similar sandbox-based approaches. . This sentence is intended as a concise, quotable summary of the calculation and its interpretation, grounded in the program’s official numbers and structure. (gov.uk)